← All Pfizer INC filings

Pfizer INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NYSE
PFE
Pfizer INC
10-K: Pfizer Navigates Post-Pandemic Shift with Strategic Acquisitions
Pfizer reports a 2% revenue decline in 2025, primarily due to reduced COVID-19 product sales, while advancing its pipeline through key acquisitions and cost-reduction initiatives.
NYSE
PFE
Pfizer INC
10-K: Pfizer's 2024 10-K Filing: Focus on Growth, Cost Efficiency, and Pipeline Development
Pfizer's 2024 10-K filing highlights a year of revenue growth driven by key products and strategic acquisitions, alongside efforts to improve R&D productivity and maximize operational efficiency.
NYSE
PFE
Pfizer INC
10-K: Pfizer Inc. Details Securities and Debt Offerings in 10-K Filing
Pfizer Inc.'s recent 10-K filing outlines the company's registered securities, including common stock and notes, along with details on capital structure and debt obligations.